GSK’s Data Transparency Initiatives:Will they Trigger a Change in Pharma Industry Practices?
The case is structured to achieve the following teaching objectives:
- Identify the factors that led to GSK committing itself to being radically open and sharing its clinical trials data publicly.
- Analyze the effectiveness of GSK’s data transparency initiatives.
- Apply a framework for implementing data transparency that respects data privacy and prevents data misuse.
|PUTTING PROFITS BEFORE SAFETY?|
|OTHERS FOLLOW SUIT|
GlaxoSmithKline plc, Data transparency, Corporate transparency, Clinical trial data, Clinical Study Register, Data secrecy, Clinical study reports, Data misuse, Patient privacy, AllTrials campaign, Food and Drug Administration